Results 111 to 120 of about 291,220 (220)

Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy

, 2017
International audiencePlatelet transfusion refractoriness (PTR) is a major adverse event in the management of acute myeloid leukemia (AML). In a series of 897 adult patients with AML receiving intensive chemotherapy, we identified 41 patients (4.8%) with
Huguet, Françoise, Luquet, Isabelle, Martinez, Salima, Françoise Huguet, Comont, Thibault, Laurent Bardiaux, Eric Delabesse, Bérard, Emilie, Isabelle Luquet, Fort, Marylise, Emilie Bérard, Christian Récher, Danièle Morère, Récher, Christian, Debiol, Bénédicte, Suzanne Tavitian, Morère, Danièle, Bénédicte Debiol, Sarah Bertoli, Thibault Comont, Marylise Fort, Bertoli, Sarah, Tavitian, Suzanne, Bardiaux, Laurent, Salima Martinez, Delabesse, Eric   +25 more
core   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

[Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness.]

, 2014
International audiencePlatelet refractoriness is a serious complication for patients receiving recurrent platelet transfusions, which can be explained by non-immune and immune causes.
Basire, A, Picard, Christophe
core  

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 10, Page 2571-2580, October 2026.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, Ping An, Wen Xie, Yujuan Guan, Qingfang Xiong, Hong Wu, Huiguo Ding, Yu Chen, Rongkuan Li, Zhili Wen, Mingqin Lu, Jinhui Yang, Zhongyin Zhou, Yongjian Zhou, Zujiang Yu, Kecan Lin, Wei Wang, Yan Huang, Yuemin Nan, Xinhua Luo, Rongshu Shi, Yi Kang, Tao Han, Shiyan Chen, Kai Wang, Yunfeng Shan, Jiaping Li, Pingguo Liu, Zheng Lu, Jun Chen, Zhen Liu, Liaoyun Zhang, Li Yang, Jifang Sheng, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu   +45 more
wiley   +1 more source

A Prevalence Study Of Platelet Alloantibodies In Multiply Transfused Thrombocytopenic Patients In HUSM. [PDF]

, 2004
Pesakit yang kerap menerima pemindahan darah adalah terdedah kepada platelet alloimmunisasi. Alloantibodi kepada platelet akan menyebabkan kegagalan kepada transfusi platelet.
Wan Mahmood, Dr Wan Haslindawani
core   +1 more source

Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders. [PDF]

Oman Med J, 2022
Neanaey WA, Deghady AA, Nafea DA, Fahmy NM, Gouda AM.   +4 more
europepmc   +1 more source

Platelet Alloantibody Specificities in Multiply Transfused Patients. [PDF]

, 2008
Transfusion plays an important role in the management of patients with hematological malignancies and disorders. Patients during the induction chemotherapy may need multiple transfusion of platelets and red cells and may develop refractoriness ...
Madhan Kumar, B K
core  

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, Volume 101, Issue 10, Page 2520-2532, October 2026.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single‐Center Japanese Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
This single‐center retrospective study evaluated hematologic immune‐related adverse events (irAEs) among 3371 patients treated with immune checkpoint inhibitors. Forty patients developed hematologic irAEs (1.2%); 85.0% of events were Grade 3 or higher, and the median time to onset was 12 weeks.
Ryo Yoshimaru, Hirotaka Nakamura, Yong‐Mei Guo, Kensuke Matsuda, Tetsuya Sakai, Yoshitaka Zenke, Kiyotaka Yoh, Kohei Shitara, Nobuaki Matsubara, Kenichi Harano, Hiromichi Nakajima, Nobuyuki Takahashi, Masafumi Ikeda, Takao Fujisawa, Saki Nakamura, Kenta Akie, Masayuki Ito, Masashi Wakabayashi, Junichiro Yuda   +18 more
wiley   +1 more source

Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders

International Journal of General Medicine, 2017
Meera Chitlur,1 Madhvi Rajpurkar,1 Michael Recht,2 Michael D Tarantino,3 Donald L Yee,4 David L Cooper,5 Sriya Gunawardena5 1Carman and Ann Adams Department of Pediatrics, Wayne State University and Children’s Hospital of Michigan, Detroit, MI, USA;
Chitlur M, Rajpurkar M, Recht M, Tarantino MD, Yee DL, Cooper DL, Gunawardena S   +6 more
doaj